Table 4.
Impact of bosentan therapy in pulmonary arterial hypertension (PAH) subgroups
| PAH sub-group | Parameter showing improvement | Study |
|---|---|---|
| Scleroderma associated PAH | Survivala time to clinical worsening 6-MWDb WHO functional class Quality of life |
Denton, Williams, Girgis, Denton, Denton, Denton, Keogh |
| HIV associated PAH | 6-MWDb WHO functional class Hemodynamics Quality of life |
Sitbon, Sitbon, Sitbon, Sitbon |
| Eisenmenger syndrome | 6-MWDb WHO functional class Hemodynamics |
Galie, Galie, Galie |
| Pediatric PAH | Survivala WHO functional class Hemodynamics |
Rosenzweig, Rosenzweig, Barst, Rosenzweig |
a
Note: compared to historical data.
b
Abbreviation: 6-MWD, six minute walk test distance.